Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 1
2017 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Impact of pre-existing or new-onset atrial fibrillation on 30-day clinical outcomes following transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial.
Hengstenberg C, Chandrasekhar J, Sartori S, Lefevre T, Mikhail G, Meneveau N, Tron C, Jeger R, Kupatt C, Vogel B, Farhan S, Sorrentino S, Sharma M, Snyder C, Husser O, Boekstegers P, Hambrecht R, Widder J, Hildick-Smith D, De Carlo M, Wijngaard P, Deliargyris E, Bernstein D, Baber U, Mehran R, Anthopoulos P, Dangas G; BRAVO-3 Investigators. Hengstenberg C, et al. Catheter Cardiovasc Interv. 2017 Nov 15;90(6):1027-1037. doi: 10.1002/ccd.27155. Epub 2017 Jun 20. Catheter Cardiovasc Interv. 2017. PMID: 28493641 Clinical Trial.
Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement: The Randomized BRAVO-3 Trial.
Dangas GD, Lefèvre T, Kupatt C, Tchetche D, Schäfer U, Dumonteil N, Webb JG, Colombo A, Windecker S, Ten Berg JM, Hildick-Smith D, Mehran R, Boekstegers P, Linke A, Tron C, Van Belle E, Asgar AW, Fach A, Jeger R, Sardella G, Hink HU, Husser O, Grube E, Deliargyris EN, Lechthaler I, Bernstein D, Wijngaard P, Anthopoulos P, Hengstenberg C; BRAVO-3 Investigators. Dangas GD, et al. J Am Coll Cardiol. 2015 Dec 29;66(25):2860-2868. doi: 10.1016/j.jacc.2015.10.003. Epub 2015 Oct 15. J Am Coll Cardiol. 2015. PMID: 26477635 Free article. Clinical Trial.
Sex-based differences in outcomes with bivalirudin or unfractionated heparin for transcatheter aortic valve replacement: Results from the BRAVO-3 randomized trial.
Asgar A, Chandrasekhar J, Mikhail G, Webb J, Lefèvre T, Tamburino C, Hildick-Smith D, Hambrecht R, Van Belle E, Widder J, Dumonteil N, Hink U, Jeger R, Linke A, Deliargyris E, Gao P, Mehran R, Hengstenberg C, Anthopoulos P, Dangas G; BRAVO-3 Investigators. Asgar A, et al. Catheter Cardiovasc Interv. 2017 Jan;89(1):144-153. doi: 10.1002/ccd.26607. Epub 2016 Aug 16. Catheter Cardiovasc Interv. 2017. PMID: 27152677
Effect of valve design and anticoagulation strategy on 30-day clinical outcomes in transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial.
Linke A, Chandrasekhar J, Sartori S, Lefevre T, van Belle E, Schaefer U, Tchetche D, Sardella G, Webb J, Colombo A, Windecker S, Vogel B, Farhan S, Sorrentino S, Sharma M, Snyder C, Asgar A, Dumonteil N, Tamburino C, Hink U, Violini R, Stella P, Bernstein D, Deliargyris E, Hengstenberg C, Baber U, Mehran R, Anthopoulos P, Dangas G; BRAVO-3 Investigators. Linke A, et al. Catheter Cardiovasc Interv. 2017 Nov 15;90(6):1016-1026. doi: 10.1002/ccd.27154. Epub 2017 Jul 19. Catheter Cardiovasc Interv. 2017. PMID: 28498562 Clinical Trial.